Dr. Shuxin Han | Xinjiang University | China
Dr. Shuxin Han is a distinguished molecular biologist and professor at Xinjiang University, widely recognized for his pioneering work in hepatobiliary and metabolic biology. With a research career spanning over two decades, Dr. Han has made major contributions to understanding how Kruppel-like factors, especially KLF15, regulate endobiotic and xenobiotic metabolism, impacting drug detoxification and metabolic disease mechanisms. He earned his Ph.D. from Kent State University and has held prestigious positions at Harvard Medical School and Case Western Reserve University. His groundbreaking studies have been published in high-impact journals like Nature Metabolism and Nature Communications, with several articles naming him as first or corresponding author. In addition to research, Dr. Han serves as a reviewer for top-tier journals in pharmacology, hepatology, and clinical science. He is also an academic leader, currently shaping the next generation of scientific talent and metabolic disease research in China.
Publication Profile:
Education:
Dr. Shuxin Han began his academic journey in Animal Sciences, earning a bachelor’s degree from Anhui Agricultural University (1994–1998). He advanced to a research assistant role at Peking University (1999–2000), where he deepened his scientific foundation. He then moved to the U.S. to pursue a Master’s in Biology at Temple University (2000–2003), followed by a Ph.D. in Molecular Biology from Kent State University (2004–2009), focusing on metabolic biology and gene regulation. This progression from general animal sciences to highly specialized molecular biology reflects a systematic and deep commitment to biomedical research. His strong academic preparation laid the foundation for a research career investigating how transcriptional regulators impact health and disease. Dr. Han’s training spans world-class institutions across both China and the United States, equipping him with diverse scientific perspectives and techniques.
Experience:
Dr. Shuxin Han has accumulated rich research and academic experience over nearly 30 years. His early career included a pivotal research assistant role at Peking University, followed by advanced training in biology and molecular biology at Temple and Kent State Universities. He completed prestigious postdoctoral training at Harvard Medical School (2009–2012) and Case Western Reserve University (2012–2015), where he later became a Senior Research Associate (2015–2019). He returned to China in 2019 as a Researcher at the University of Science and Technology of China First Affiliated Hospital, simultaneously engaging in academic duties at the university until 2023. Currently, he serves as a Professor and Academic Leader at Xinjiang University. Throughout his career, Dr. Han has built strong international collaborations, led research groups, and guided innovative projects in metabolic biology, demonstrating his leadership, research excellence, and academic mentorship capabilities.
Research Focus:
Dr. Shuxin Han’s research centers on the molecular regulation of metabolism, particularly focusing on the hepatobiliary and gastrointestinal systems. His work has elucidated the critical role of the Kruppel-like factor (KLF) family, especially KLF15, in controlling endobiotic and xenobiotic metabolism (EXM). These pathways govern how the body metabolizes both internal compounds and external substances like drugs. Dr. Han’s studies have shown that KLF15 acts as a master regulator, influencing drug resistance, liver injury, and metabolic homeostasis. His discoveries offer new insight into personalized medicine and treatment for metabolic disorders and drug-related toxicities. With numerous first-author and corresponding-author publications in journals such as Nature Metabolism, Nature Communications, and Drug Metabolism and Disposition, his work has significantly impacted both fundamental science and clinical applications. He is also active in peer-reviewing for top-tier journals and is recognized for his leadership in translational research.
Publications Top Notes:
-
Unveiling KLF15 as the Key Regulator of Cyclosporine A Metabolism and Adverse Effects – Drug Metabolism and Disposition, 2025
-
Distribution and Functional Significance of KLF15 in Mouse Cerebellum – Molecular Brain, 2025
-
Personalized Statin Therapy: Targeting Metabolic Processes – Heliyon, 2025
-
Current Status and New Directions for Hepatocellular Carcinoma Diagnosis – Liver Research, 2024
-
KLF15-Cyp3a11 Axis Regulates Rifampicin-Induced Liver Injury – Drug Metabolism and Disposition, 2024
-
Advancing Drug Delivery and Bioengineering in Liver Research – Bioengineering and Translational Medicine, 2024
-
Advances in IL-7 Research on Tumor Therapy – Pharmaceuticals, 2024 (Co-author)
-
Pathogenic Mechanisms in Alcoholic Liver Disease – Journal of Translational Medicine, 2023
-
Beta-Hydroxybutyrate Effects on iPSC-Derived Cardiac Myocytes – Biomolecules, 2022
-
Interactions Between Intestinal Flora and Bile Acids – International Journal of Molecular Sciences, 2022 (Corresponding author)
Conclusion:
In conclusion, Dr. Shuxin Han is a highly deserving candidate for the Best Researcher Award. His pioneering work on KLF15 and metabolic regulation has reshaped fundamental understanding in the field of hepatobiliary biology and pharmacology. His academic background, research productivity, international experience, and editorial service all reflect a well-rounded and impactful scientist. While there is room to increase clinical translation and international engagement, the depth, originality, and consistency of his research make him a strong contender for this recognition. Honoring Dr. Han with this award would acknowledge a career dedicated to scientific advancement with substantial implications for human health and drug therapy.